Literature DB >> 8640757

The blood group ABO gene transcript is down-regulated in human bladder tumors and growth-stimulated urothelial cell lines.

T F Orntoft1, P Meldgaard, B Pedersen, H Wolf.   

Abstract

The molecular mechanism that in human bladder tumors leads to the loss of blood group ABO glycosyltransferase activity and, thereby, the loss of ABO antigens was investigated. In 15 tumors and 3 normal biopsies from blood group AB individuals and 7 tumors and 3 normal biopsies from blood group O individuals, mRNA was detected by a reverse transcription PCR (RT-PCR) assay, and the ABO blood group structure was determined by immunohistology. The RT-PCR spanned several introns in the ABO gene to exclude DNA contamination, and the RT-PCR product was shown to reflect the ABO gene message by dideoxy sequencing. The ABO mRNA was present in normal urothelium and low-grade tumors but disappeared from high grade tumors. This correlation to tumor grade was significant (P<0.04). Immunohistochemistry with monoclonal anti-blood group antibodies showed a complete correlation between the presence of mRNA and the presence of AB carbohydrate structures on cell surfaces. In two urothelial cell lines, genotyped as A/- and A/A, growth stimulation with the cholera toxin B subunit led to a total loss of ABO mRNA, and epidermal growth factor stimulation had an identical effect on one of the cell lines. We conclude that the ABO glycosylation in normal and malignant urothelium is regulated at the mRNA level, and that a mechanism associated with cell proliferation may trigger down-regulation of ABO mRNA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640757

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Perspectives on the significance of altered glycosylation of glycoproteins in cancer.

Authors:  Y J Kim; A Varki
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

2.  Deletion of A-antigen in a human cancer cell line is associated with reduced promoter activity of CBF/NF-Y binding region, and possibly with enhanced DNA methylation of A transferase promoter.

Authors:  S Iwamoto; D A Withers; K Handa; S Hakomori
Journal:  Glycoconj J       Date:  1999-10       Impact factor: 2.916

3.  Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases.

Authors:  T Petretti; W Kemmner; B Schulze; P M Schlag
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

4.  Functional analysis of the mismatch repair system in bladder cancer.

Authors:  T Thykjaer; M Christensen; A B Clark; L R Hansen; T A Kunkel; T F Ørntoft
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

5.  Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?

Authors:  Guido Moll; Annika Hult; Lena von Bahr; Jessica J Alm; Nina Heldring; Osama A Hamad; Lillemor Stenbeck-Funke; Stella Larsson; Yuji Teramura; Helene Roelofs; Bo Nilsson; Willem E Fibbe; Martin L Olsson; Katarina Le Blanc
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

6.  AB0/Rhesus Blood Group Does Not Influence Clinicopathological Tumor Characteristics or Oncological Outcome in Patients Undergoing Radical Prostatectomy.

Authors:  Su Jung Oh; Philipp Mandel; Felix K H Chun; Pierre Tennstedt; Sven Peine; Jan Lukas Hohenhorst; Jens Hiller; Markus Graefen; Derya Tilki; Thomas Steuber
Journal:  Front Surg       Date:  2017-12-18

7.  Association between Blood Group and Nonmelanoma Skin Cancers (Basal Cell Carcinoma and Squamous Cell Carcinoma).

Authors:  Dijana Celić; Jasna Lipozenčić; Branko Kolarić; Goran Ferenčak; Jolanda Kanižaj Rajković; Tajana Borlinić
Journal:  Int J Environ Res Public Health       Date:  2019-06-27       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.